IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

$672.04

Updated: 04/11/2026, 10:31:10

Market Cap
$52.94B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

USD
NASDAQ
CEO: Michael Erickson
Employees: 11,000
https://www.idexx.com
Asset Summaries
Latest generated summaries for IDXX

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
IDXX-10-k-fy2025.html2.8 MBtext/htmlENFiled 20/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 65 KPI observations

Revenue

$4.3B

FY 2025 · Reported

Net income

$1.1B

FY 2025 · Reported

Gross margin

61.8%

FY 2025 · Calculated

Free cash flow

$1.1B

FY 2025 · Calculated

R&D intensity

5.8%

FY 2025 · Calculated

Share repurchases

$1.2B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

CAG revenue by product/service line FY2025
New IDEXX inVue Dx Analyzer drove instrument revenue
Connected IoT and cloud-based product portfolio

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States: 0.6% of reported revenueNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
United States
+69.6%
United States
+66.3%
United States
+2.6%
United States
+0.6%

How the business makes money

Reportable segments

Reportable segments: CAG, Water, and LPD; Other reconciling

98%
Source evidence
“We exclude foreign currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations”

CAG revenue by product/service line FY2025

CAG Diagnostics recurring $3,407.2M (+8.9%); instruments $200.2M (+51.8%); Vet software/imaging $345.9M (+10.6%)

99%
Source evidence
“CAG Diagnostics recurring revenue:$3,407,199 $3,129,492 $277,707 8.9%”

New IDEXX inVue Dx Analyzer drove instrument revenue

Instrument revenue +51.8% primarily from new IDEXX inVue Dx Analyzer placements

97%
Source evidence
“The increase in instrument revenue was primarily due to placements of our new IDEXX inVue Dx Analyzer”

Connected IoT and cloud-based product portfolio

Cloud-based veterinary practice management systems, customer communication tools, and connected IoT devices (IDEXX VetLab Stations and analyzers)

90%
Source evidence
“our connected IoT devices (e.g., IDEXX VetLab Stations and analyzers) that enable our integrated, comprehensive diagnostic solution for veterinary practices”

US vs international revenue mix

FY2025 US $2,752.8M; International $1,550.9M (+13.7%)

98%
Source evidence
“United States2,752,785 2,533,174 219,611 8.7%”

FY2025 revenue by segment and geography

FY2025 total revenue $4,303,702K (+10.4% reported, +9.6% organic); CAG $3,953,285K; Water $201,149K; LPD $131,787K

99%
Source evidence
“Total Company$4,303,702 $3,897,504 $406,198 10.4%0.8%— 9.6%”

Operations and dependencies

USD-manufactured product sold internationally

~23% of 2025 revenue (22% 2024, 21% 2023) from USD-manufactured products sold internationally in local currencies

98%
Source evidence
“For the year ended December 31, 2025, approximately 23% of our consolidated revenue was derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies, compared to 22% and 21% for the years ended December 31, 2024 and 2023, respectively.”

Hedged currency list

Hedges 75%-85% of intercompany product purchase/sale exposure in euro, British pound, Canadian dollar, Japanese yen, Australian dollar; notional $397.6M (2025) vs $325.7M (2024)

98%
Source evidence
“We target to hedge approximately 75% to 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar.”

FX sensitivity

A 1% strengthening of the U.S. dollar would reduce revenue by ~$16 million and operating income by ~$5 million, net of hedges

95%
Source evidence
“a 1% strengthening of the U.S. dollar would reduce revenue by approximately $16 million and operating income by approximately $5 million, net of hedge positions.”

FX impact on FY2025 results

FX increased FY2025 total revenue growth by 0.8%; FX gains/losses centrally managed

95%
Source evidence
“The impact from changes in foreign currency exchange rates increased total revenue growth by 0.8%.”

Global workforce size and gender mix

~11,000 regular full-time and part-time employees in ~34 countries as of December 31, 2025; 41% men, 59% women

98%
Source evidence
“As of December 31, 2025, we had approximately 11,000 regular full-time and part-time employees in approximately 34 countries around the world”

Positioning and strategy

Volume growth drivers

Volume growth from new business gains, expanded test menu, higher utilization

95%
Source evidence
“Volume growth was supported by new business gains, our expanded menu of available tests, and higher utilization in our loyal customer base”

Risks, financing, and outlook

Supply chain cost exposure to inflation, tariffs, and duties

Cost of goods may be adversely impacted by inflation (including wage inflation), supply restrictions, tariffs or duties, and regulatory requirements

94%
Source evidence
“unanticipated price increases due to factors such as inflation (including wage inflation), supply restrictions beyond our control or the control of our suppliers, the imposition of tariffs or duties”

Inflationary product and labor costs

Gross margin partly offset by inflationary product and labor costs

90%
Source evidence
“which offset the impacts from higher product and labor costs due to, in part, inflationary cost effects”

Debt covenant and interest rate risk

Variable-rate (SOFR-based) Credit Facility with financial covenants; senior notes carry prepayment penalty on early repayment

95%
Source evidence
“Borrowings under our Credit Facility bear interest at variable rates, including rates based on the Secured Overnight Financing Rate (“SOFR”), exposing us to interest rate risk.”

2026 FX impact outlook

2026 FX tailwind expected: +$28M revenue, +$22M operating profit, +$0.22 diluted EPS; assumes EUR $1.16, GBP $1.33, CAD $0.72, AUD $0.66, JPY ¥157

95%
Source evidence
“we anticipate year-over-year changes will increase our revenues, operating profit, and diluted earnings per share in the year ending December 31, 2026, by approximately $28 million, $22 million, and $0.22 per share, respectively.”

Macro and sector headwinds constrain growth

Volume growth partially constrained by macroeconomic and sector headwinds

90%
Source evidence
“partially constrained by macroeconomic and sector headwinds”

2025 stock price range

2025 stock price range: $361.04 low to $766.68 high

95%
Source evidence
“in spite of our operating performance as demonstrated during 2025 where the range of our stock price was from a low of $361.04 to a high of $766.68.”

EPA-approved water testing products

Tecta, Colilert, Colilert-18, Colisure, Quanti-Tray, Filta-Max xpress, Enterolert, SimPlate approved by the EPA for various regulatory programs

98%
Source evidence
“Our Tecta Systems with the Tectalert EC/TC medium, Colilert, Colilert-18, Colisure, Quanti-Tray, Filta-Max xpress, Enterolert, and SimPlate for heterotrophic plate counts products have been approved by the EPA”

Dairy testing FDA/NCIMS regulation with two FDA-validated products

Dairy products in NCIMS milk-monitoring programs are FDA-regulated; IDEXX has two FDA-validated test products, SNAP NBL and SNAP Tetra, for sale in the U.S.

97%
Source evidence
“IDEXX has two FDA-validated test products, SNAP NBL and SNAP Tetra, for sale in the U.S.”

Human point-of-care electrolyte and blood gas analyzers regulated as FDA Class I/II medical devices

Human point-of-care electrolyte and blood gas analyzers are FDA Class I/II medical devices subject to cGMP

96%
Source evidence
“Our human point-of-care electrolyte and blood gas analyzers are classified by the FDA as Class I and/or Class II medical devices”

Broad chemical/environmental product regulations (RoHS, REACH, EMC, Biocidal Products Regulation)

IDEXX products must comply with global regulations including EU RoHS, EMC, REACH, and Biocidal Products Regulation; similar regimes in Australia, China, Turkey, Korea

96%
Source evidence
“All IDEXX products must comply with applicable global product regulations, including those governing consumer product safety and materials requirements such as the Europeans Union's Electromagnetic Compatibility (“EMC”) Directive”

AI and data privacy regulations

Products using AI may be subject to new regulations including the EU Artificial Intelligence Act enacted in August 2024; also subject to GDPR, EU Data Act, FCPA, UK Bribery Act

95%
Source evidence
“including the European Union’s Artificial Intelligence Act enacted in August 2024”

PFAS regulatory attention

PFAS in certain IDEXX products face increasing regulation; Minnesota will ban PFAS in products impacting water products beginning in 2032

94%
Source evidence
“Minnesota will implement a regulation banning PFAS in products that impact water products beginning in 2032”

Third-party supplier dependency including sole/single sources

Relies on third-party suppliers including sole/single sources such as Ortho; proprietary products cannot be readily replaced; mitigations include escrow and safety stock

97%
Source evidence
“we currently purchase many products, components, and materials from sole or single sources, such as Ortho”

Biologic product manufacturing complexity

Many rapid assay, livestock/poultry, water, and dairy products are biologics with inherently variable biological materials; manufacturing failures could force recalls

96%
Source evidence
“Many of our rapid assay, livestock and poultry diagnostic, water, and dairy products are biologic products that include biological materials, such as antibodies, cells, and sera”

Distributor dependence risk

Reliance on distributors who may promote competitors' products; loss of key distributors could reduce revenue

95%
Source evidence
“We may rely on one or more key distributors for a product or a region, and the loss of these distributors could reduce our revenue.”

AI use in products and operations creates risk

IDEXX builds AI into many product and service offerings and internal operations; flawed algorithms, insufficient or infringing datasets could cause reputational harm or liability

95%
Source evidence
“We have built, and expect to continue to build, AI into many of our product and service offerings, and we expect this element of our business to grow”

Key personnel and CEO transition risk

Planned CEO transition in May 2026 announced January 13, 2026; dependence on key personnel

95%
Source evidence
“such as our planned CEO transition in May 2026 that we announced on January 13, 2026”

Cybersecurity and IT systems risk

Dependence on IT systems, cloud providers, and connected IoT devices; past cyberattacks experienced; AI-enhanced threats growing

95%
Source evidence
“the use of AI and other emerging technologies by threat actors is growing, enabling more sophisticated and effective cybersecurity attacks and phishing and social engineering schemes and further increasing attack volume and frequency.”

Cloud-based software delivery dependency

Relies on third-party suppliers to provide cloud-based infrastructure for cloud-based software solutions; disruptions could substantially decrease sales and reduce recurring revenues

93%
Source evidence
“provide the cloud-based infrastructure through which we deliver our cloud-based software solutions”

Operations/supply chain disruption risk

External events (disasters, pandemics, tariffs, raw material unavailability) could disrupt operations, supply chain, and logistics network

90%
Source evidence
“the imposition of regulations, trade protection measures, tariffs, duties, import/export restrictions, quotas or embargoes on key components; transportation failures affecting the supply and shipment of materials and finished goods; and the unavailability of raw materials.”

Macroeconomic and inflation risk

Macroeconomic conditions, inflation, wages, and interest rates may raise costs and reduce veterinary diagnostic demand

90%
Source evidence
“For our veterinary customers, these events may negatively affect the number of patient visits and elective procedures, and the volume of diagnostic utilization, which could adversely affect our revenues.”

Material exposure graph

Healthcare / companion animal veterinary diagnostics
Revenue Exposure

CAG segment ($3.95B of $4.30B revenue) is driven by companion animal healthcare testing volumes and prices.

Relevance 95·Dependency 92·Confidence 95
Source evidence
“growth in CAG Diagnostics recurring revenue, including benefits from higher volumes and higher realized prices”
IDEXX VetLab consumables
Demand Driver

Largest recurring product line at $1,496.8M, +14.8%, driven by installed base growth and expanded test menu.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“IDEXX VetLab consumables1,496,752 1,303,250 193,502 14.8%”
IDEXX inVue Dx Analyzer
Demand Driver

New analyzer placements drove 51.8% reported growth in CAG Diagnostics capital - instruments revenue.

Relevance 90·Dependency 70·Confidence 95
Source evidence
“primarily due to placements of our new IDEXX inVue Dx Analyzer”
Ortho
Supplier Dependency

Ortho is a sole or single-source supplier; its products are proprietary and cannot be readily replaced, used in instruments, consumables and accessories; livestock and poultry diagnostic tests, dairy testing products; and water testing products.

Relevance 85·Dependency 90·Confidence 95
Source evidence
“we currently purchase many products, components, and materials from sole or single sources, such as Ortho”
Veterinary practices (loyal customer base)
Demand Driver

Higher utilization in loyal customer base and high retention rates support consumable and testing volume growth.

Relevance 85·Dependency 85·Confidence 90
Source evidence
“higher utilization in our loyal customer base, partially constrained by macroeconomic and sector headwinds”
IDEXX VetLab instruments
Demand Driver

Installed base growth of point-of-care analyzers drives recurring consumables, services, and accessories demand, a core revenue mechanism.

Relevance 85·Dependency 75·Confidence 93
Source evidence
“grow our installed base of instruments, and increase demand for related recurring sales of consumable products, services, and accessories”
Reference laboratory diagnostic and consulting services
Revenue Exposure

$1,424.1M revenue, +6.6%, driven by higher testing volumes in North America, Europe, and Asia Pacific.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“higher testing volumes in North America, Europe, and Asia Pacific and higher realized prices”
biological materials
Supplier Dependency

Biologic products depend on antibodies, cells, and sera; sourcing and manufacturing variability can prevent supply and force recalls.

Relevance 80·Dependency 85·Confidence 95
Source evidence
“Many of our rapid assay, livestock and poultry diagnostic, water, and dairy products are biologic products that include biological materials, such as antibodies, cells, and sera”
Foreign currencies (international revenue)
Revenue Exposure

International revenue of $1,550.9M (36% of total) exposes results to FX; FX added 0.8% to revenue growth; transaction gains/losses centrally managed.

Relevance 80·Dependency 55·Confidence 92
Source evidence
“International1,550,917 1,364,330 186,587 13.7%2.3%— 11.3%”
Third-party distributors
Customer Exposure

IDEXX depends on distributors to promote and create demand; loss of key distributors or changes in their inventory levels could reduce revenue growth.

Relevance 75·Dependency 70·Confidence 95
Source evidence
“we are dependent on these distributors to promote and create demand for our products”
cloud_computing
Technology Dependency

Cloud-based software solutions depend on third-party cloud infrastructure; disruptions could decrease sales and recurring revenues.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“provide the cloud-based infrastructure through which we deliver our cloud-based software solutions”
tariffs
Cost Driver

Imposition of tariffs or duties and inflation including wage inflation can raise supply chain costs and cost of goods.

Relevance 70·Dependency 60·Confidence 92
Source evidence
“the imposition of tariffs or duties, or regulatory requirements regarding the importation, exportation, composition, or production processes of the goods or materials provided by our suppliers”
PFAS regulations
Regulatory Exposure

Certain IDEXX products may contain PFAS, subject to increasing EU, EPA, and state regulation including a Minnesota ban starting 2032; compliance may require product reformulation.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“PFAS (per- and polyfluoroalkyl substances), which may be contained in certain IDEXX products, are a subject of increasing regulatory attention”
Euro
Currency Exposure

Euro is one of the primary hedged currencies for intercompany purchases/sales; 2026 outlook assumes euro at $1.16.

Relevance 70·Dependency 55·Confidence 95
Source evidence
“We primarily hedge intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar.”
Inflation
Cost Driver

Inflationary product and labor costs offset pricing and productivity benefits in gross margin.

Relevance 70·Dependency 45·Confidence 88
Source evidence
“offset the impacts from higher product and labor costs due to, in part, inflationary cost effects”
Catalyst instrument platform
Demand Driver

Customer shift of pancreatic lipase testing to Catalyst platform decreased rapid assay revenue (-3.0%).

Relevance 65·Dependency 55·Confidence 85
Source evidence
“a shift of customers' pancreatic lipase testing to our Catalyst instrument platform”
Consumer spending
Demand Driver

Macroeconomic conditions affecting consumer spending influence veterinary patient visits, elective procedures, and diagnostic utilization volumes.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“For our veterinary customers, these events may negatively affect the number of patient visits and elective procedures, and the volume of diagnostic utilization”
Cloud computing
Technology Dependency

Cloud-based products and IoT-connected diagnostic devices rely on third-party cloud providers; disruption or breach could impair product delivery.

Relevance 60·Dependency 55·Confidence 90
Source evidence
“these products and services rely on third-party providers for cloud computing and storage”
EU AI Act
Regulatory Exposure

IDEXX products incorporating AI may be subject to emerging regulations including the EU AI Act enacted August 2024.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“Our products that use generative or other forms of artificial intelligence (“AI”) may also be subject to new and emerging law and regulations, including the European Union’s Artificial Intelligence Act enacted in August 2024”
Inflation
Cost Driver

Inflationary pressures, wage increases, and rising interest rates are disclosed as factors that could increase costs and disrupt operations.

Relevance 55·Dependency 40·Confidence 90
Source evidence
“inflationary pressures, which may increase costs for materials and finished goods”
Interest rates
Cost Driver

Variable-rate SOFR-based Credit Facility borrowings expose IDEXX to rising interest rates increasing debt service obligations.

Relevance 50·Dependency 40·Confidence 95
Source evidence
“If interest rates were to increase, our debt service obligations under our variable-rate Credit Facility would increase even if the principal amount borrowed remained the same.”
Tariffs and trade measures
Regulatory Exposure

Tariffs, duties, import/export restrictions, quotas, and embargoes on key components are disclosed as potential disruptions to supply chain and logistics.

Relevance 50·Dependency 40·Confidence 90
Source evidence
“the imposition of regulations, trade protection measures, tariffs, duties, import/export restrictions, quotas or embargoes on key components”
Full company information
Latest profile, trading, valuation, and identifier data stored for IDXX.
Share price
$672.04
Market cap
$52.94B
Exchange
NASDAQ
Currency
USD
CEO
Michael Erickson
Employees
11,000
IPO date
21/06/1991
Beta
1.546
Last dividend
$0.00
Day range
$655.52 – $681.50
52-week range
$500.61 – $769.98
1-day performance
0.06%
1-year performance
34.24%
Current drawdown (1Y)
-12.72%
CIK
0000874716
CUSIP
45168D104
ISIN
US45168D1046
Created
07/12/2025, 04:40:35
Last update
04/11/2026, 10:31:10

Track IDEXX Laboratories, Inc. with an AI analyst

See which prediction-market events move IDXX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to IDXX from your Railway `news_articles` table.

Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock

Zacks Investment Research • STOCK • 11/06/2026, 12:52:04

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

Zacks Investment Research • STOCK • 09/06/2026, 12:46:12

IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference

MarketBeat • STOCK • 30/05/2026, 09:02:41

IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript

Seeking Alpha • STOCK • 27/05/2026, 15:27:05

IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day

Business Wire • STOCK • 14/05/2026, 18:34:00

IDEXX Laboratories (NASDAQ: IDXX) Reports Strong Quarterly Results, Exceeding Expectations

Market Data • Market Data • 05/05/2026, 21:01:12

IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 05/05/2026, 16:11:13

IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up

Zacks Investment Research • STOCK • 05/05/2026, 13:31:21

Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates

Zacks Investment Research • STOCK • 05/05/2026, 10:45:30

IDEXX Laboratories Announces First Quarter Results

Business Wire • STOCK • 05/05/2026, 08:30:00

Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings

Zacks Investment Research • STOCK • 01/05/2026, 12:11:20

IDEXX Laboratories (NASDAQ: IDXX) Stock Analysis: Neutral Rating Amid Valuation Concerns and Growth Drivers

Market Data • Market Data • 28/04/2026, 16:11:01